Tuesday, November 14, 2006
Article in the Wall Street Journal -- FDA Urges Caution on Flu Drug, by Patricia Kowsmann:
Food and Drug Administration staff recommended that the label for Roche Holding AG's flu drug Tamiflu be updated to include a precaution related to possible psychiatric problems in patients who take it.
The move follows a 10-month review that found 103 cases of "neuropsychiatric adverse events," including the death of a 14-year-old boy who fell after climbing on a balcony railing.
Here's a link to the New York Times article, Monitor Children on Flu Drug, F.D.A. Urges, by the Associated Press; to the Washington Post article, Flu Drug Label Will Warn of Risks, FDA Says, by Andrew Bridges; and to the Los Angeles Times article, Tamiflu linked to abnormal behavior, by Jia-Rui Chong.